Pulmonary drug delivery is considered to be an alternative system to deliver drugs to the lungs. Pulmonary route of drug delivery gaining much importance in the present day research field as it enables to target the drug delivery directly to lung both for local and systemic treatment. A growing attention has been given to the development of targeted drug delivery systems due to the limitations associated with the conventional treatment of various chronic diseases. respiratory system is divided into the airway and the respiratory region. Aerosol inhalation and intratracheal instillation are used to administer drugs through the pulmonary route. The aerosol inhalation technique offers advantages such as higher penetration and uniform distribution of drug particles in the peripheral or the alveolar region of the lungs. The three most commonly used aerosols are ultrasonic nebulizers or jets, metered dose inhalers (MDI), and dry powder inhaler (DPI). Dry powder inhalers (DPIs) are used majorly for the treatment of asthma and COPD.
The global pulmonary drug delivery systems market report estimates the market size (Revenue USD million – 2014 to 2021) for key market segments based on product type (dry powder inhalers, metered dose inhalers, nebulizers), its medical applications (asthma, COPD, cystic fibrosis) and forecasts growth trends (CAGR% – 2017 to 2021).
The global pulmonary drug delivery systems market report also provides the detailed market landscape, market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments. The global pulmonary drug delivery systems market research report is divided by geography (regional and country based) into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World.
Major players operating in the global pulmonary drug delivery systems market and included in this report are 3M Health Care, CareFusion Corporation, GlaxoSmithKline Plc., Novartis AG, Omron Healthcare, Inc., PARI Respiratory Equipment Inc., and Philips Respironics, Inc.